Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 2Brain Neoplasms 2Skin Neoplasms 1Recurrence 1Lung Neoplasms 1Kidney Neoplasms 1Health Behavior 1Child Behavior 1Carcinoma, Renal Cell 1Breast Neoplasms 1Behavior 1

Interventions

pembrolizumab 22Nivolumab 17Magnetic Resonance Spectroscopy 12Specimen Handling 10Cyclophosphamide 9Radiosurgery 7Drug Therapy 6Radiotherapy 5Paclitaxel 5Ipilimumab 5fludarabine 4Biopsy 4trametinib 3sargramostim 3Trastuzumab 3Taxes 3Pemetrexed 3Metformin 3Interleukin-2 3Immunoglobulin G 3Gemcitabine 3Carboplatin 3Bevacizumab 3tremelimumab 2temsirolimus 2poly ICLC 2pertuzumab 2osimertinib 2motexafin gadolinium 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Spermine Synthase × Dermatologic × Clear all
NCT03075072 2024-10-23

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Dana-Farber Cancer Institute

Phase NA Active not recruiting
196 enrolled
BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡